Investor Presentation November 26, 2013
Forward-Looking Statements This presentation may contain forward-looking statements as defined under U.S. federal securities laws. These statements reflect management's current knowledge, assumptions, beliefs, estimates, and expectations and express management's current view of future performance, results, and trends. Forward-looking statements may be identified by their use of terms such as anticipate, believe, could, estimate, expect, intend, may, plan, predict, project, will, and other similar terms. Forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to materially differ from those described in the forward-looking statements. The reader should not place undue reliance on forward-looking statements. Such statements are made as of the date of this presentation, and we undertake no obligation to update such statements after this date. Risks and uncertainties that could cause our actual results to materially differ from those described in forward-looking statements are discussed in our filings with the Securities and Exchange Commission (including those described in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2012, and as may be supplemented in our Quarterly Reports on Form 10-Q). By way of example and without implied limitation, such risks and uncertainties include: failure to realize the anticipated benefits of the Biotech International acquisition in whole or in part, and unexpected liabilities and/or erroneous financial estimates and projections for the acquired business; failure to realize the anticipated financial and other benefits from the acquisition of BioMimetic Therapeutics, Inc. or a delay in realization thereof; failure to obtain, or a delay in obtaining, FDA approval of Augment Bone Graft, or a material limitation on the scope of such approval; lower than anticipated market acceptance of, or annual market demand for, Augment Bone Graft; failure to obtain necessary approvals, or other intervening events, which could delay or prevent the previously announced sale of our hip/knee business from closing; future actions of the United States Attorney's office, the FDA, the Department of Health and Human Services or other U.S. or foreign government authorities, including those resulting from increased scrutiny under the Foreign Corrupt Practices Act and similar laws, that could delay, limit or suspend our development, manufacturing, commercialization and sale of products, or result in seizures, injunctions, monetary sanctions or criminal or civil liabilities; failure to obtain the FDA or other regulatory clearances needed to market and sell our products; any actual or alleged breach of the Corporate Integrity Agreement to which we are subject through September 2015 which could expose us to significant liability including exclusion from Medicare, Medicaid and other federal healthcare programs, potential criminal prosecution, and civil and criminal fines or penalties; adverse outcomes in existing product liability litigation; new product liability claims; inadequate insurance coverage; the possibility of private securities litigation or shareholder derivative suits; demand for and market acceptance of our new and existing products; potentially burdensome tax measures; recently enacted healthcare laws and changes in product reimbursement which could generate downward pressure on our product pricing; lack of suitable business development opportunities; inability to capitalize on business development opportunities; product quality or patient safety issues; challenges to our intellectual property rights; geographic and product mix impact on our sales; our inability to retain key sales representatives, independent distributors and other personnel or to attract new talent; inventory reductions or fluctuations in buying patterns by wholesalers or distributors; inability to realize the anticipated benefits of restructuring initiatives; negative impact of the commercial and credit environment on us, our customers and our suppliers; and the potentially negative effect of our ongoing compliance enhancements on our relationships with customers and our ability to deliver timely and effective medical education, clinical studies, and new products. 2
Use of Non-GAAP Financial Measures Wright Medical uses certain non-gaap financial measures in this presentation. Wright Medical uses non-gaap financial measures as supplemental measures of performance and believes these measures provide useful information to investors in evaluating our operations, period over period. However, non-gaap financial measures have limitations as analytical tools, and should not be considered in isolation or as a substitute for or as superior to Wright Medical s financial results prepared in accordance with GAAP. In addition, investors should note that any non-gaap financial measures Wright Medical uses may not be the same non-gaap financial measures, and may not be calculated in the same manner, as that of other companies. We have posted a reconciliation of our non-gaap financial measures to the most directly comparable GAAP financial measures on our website at www.wmt.com. 3
Wright Medical: A Leader in Our Space Orthopaedic medical device company Global Sales from continuing operations 2013E ~$238M (1) Market cap (as of 11/26/13) ~$1.4B Countries >60 1 Midpoint of guidance range communicated on 11/4/2013. The fact that we include these projections in this presentation should not be taken to mean that these amounts continue to be our projections as of any subsequent date. 4
W R I G H T M E D I C A L Historically Positioned in Two Large Markets Business Market Size / Growth Our Position / Strategic Focus Extremities (incl. Biologics) ~45% of sales Size: ~$3.5B (1) Market Growth: ~8-10% Recognized leader in Foot & Ankle Primarily US Focus: growth Ortho-Recon (Hips and Knees) ~55% of sales Size: ~$13B (2) Market Growth: ~0-3% Mid-sized player Primarily International Focus: efficiency, cash generation 1 US Market 2012 Millennium Research Group, Management Estimates 2 Worldwide Market 2011 Millennium Research Group, Management Estimates 5
Entered Into Agreement to Divest OrthoRecon Business June 19, 2013: Wright and MicroPort Scientific Corporation Enter Into Definitive Agreement Under Which MicroPort Will Acquire Wright s OrthoRecon Business Transaction transforms Wright Medical into high-growth Extremities and Biologics pure play Purchase price of $290 million in cash, subject to a net working capital adjustment Expect to close by end of Q4 of 2013 6
L A S T T W O Y E A R S A Transformed Business High Growth Profile Wright Medical Focus on strengthening Extremities Divest slower growth OrthoRecon segment Low Low Business Focus High 7
Focused On Higher Growth Segments of the Orthopedics Market 2011-2016 CAGR 10% 7-8% 7% 7% 6% 3-4% 3% 2-3% Foot & Ankle Sports Medicine Biologics Extremities Trauma Knee Spine Hip Source: 2011 & 2012 Millennium Research Group, 2012 Life Science Intelligence, Management Estimates 8
T R A N S F O R M I N G T H E C O M P A N Y Results Indicate Execution is On Track A Few Key Numbers Increase US Foot and Ankle Sales Productivity Q3, 2013 Continued Investment in Physician Training 2013 Accelerate Growth in Global Foot & Ankle Q3, 2013 Sales from Continuing Operations Q3, 2013 $ 780K ~2,100 +22 % +14 % vs. $700K in 2012 and $600K in 2011 trained vs. 2,000 in 2012 and 600 in 2011 vs. 14% in Q3, 2012 vs. 2% in Q3, 2012 9
Accelerating Foot & Ankle Growth Foot & Ankle Growth (Global Constant Currency) 23% 15% 9% 2011 2012 YTD 3Q 2013 10
T H E M A R K E T Focused on Most Attractive Segment of Extremities Market Breakdown of $3.5B US Extremities Market Foot & Ankle: An Attractive Segment Upper Extremity $2.4B 27,000 surgeons Foot & Ankle $1.1B 7,500 surgeons and podiatrists More concentrated call point Complex treatment issues, less mature products need innovative solutions significant mix opportunity Strong growth drivers trauma osteoarthritis diabetes obesity High margin Source: Millennium Research Group, Management Estimates Underpenetrated market significant opportunity for international expansion 11
S T R E N G T H S : Recognized Leader in Foot and Ankle Direct US foot & ankle sales organization Most comprehensive foot & ankle product portfolio Continued investment in R&D VALOR NAIL Fixation INBONE Total Ankle SIDEKICK Fixation AM Surgical Endoscopic Blade CHARLOTTE CLAW 2.7mm Implant DARCO Screws CHARLOTTE CLAW 3.5mm Implant CHARLOTTE Compression SIDEKICK Stealth Fixation CHARLOTTE 7.0 MUC Screw CHARLOTTE Jones Fracture Screw LIS FRANC Plate CHARLOTTE 3.0 MUC Screw BIOFOAM Wedge ORTHOLOC Plate GRAFTJACKET Regenerative Tissue Matrix DART-FIRE Screws ORTHOSPHERE Implant DARCO DPS Plate CHARLOTTE Snap-Off Screw BIOARCH Implant ORTHOLOC Plate SWANSON Hammer Toe Implant ENDO-FUSE Rods and Beams DARCO PIA Plate DARCO LPS Plate PRO-TOE Hammer Toe Fixation LPT Toe Implant DARCO RPS Plate DARCO BOW Plate DARCO MPJ Plate CORETRAK Tube Fixator SWANSON Great Toe MTP Plate 12
S T R A T E G I C F O C U S : G R O W T H Maximize the Foot & Ankle Opportunity Grow base business next generation products INBONE II and PROPHECY Total Ankle Replacement System PRO-TOE Hammertoe Fixation System ORTHOLOC 3Di Foot Reconstruction Plating System CLAW II Polyaxial Compression Plating System Our Goal Accelerate Growth in Foot & Ankle Market Planned 2014 launches INFINITY Total Ankle Replacement System, New PRO-TOE offering Continued investment in medical education Targeting >50% increase in US sales force productivity to $1M in 2014 International market development 13
What s Next? Near-Term Priorities Improve gross margins Momentum is Building Continued progress on inventory initiatives Targeted M&A International expansion Close MicroPort transaction Productivity gains in US Foot & Ankle 14
I N T E R N A T I O N A L E X P A N S I O N : Acquisition of Biotech International November 15, 2013: Wright Completes Acquisition of Biotech International Significantly expands Wright s direct sales channel in France and international distribution network Adds complementary extremity product portfolio to further accelerate growth opportunities in global Extremities business Total consideration up to $80 million: $75M paid at closing (~$55M cash and ~$20M in stock); plus contingent payments of up to $5M cash upon achievement of revenue milestones in 2014 and 2015 All Wright common stock subject to one-year lockup 15
A U G M E N T B O N E G R A F T : Status of FDA Appeal of Not Approvable Letter Received Not Approvable Letter for Augment Bone Graft from FDA dated August 6, 2013: FDA stated the following: concerned that the population enrolled was predominantly low risk and, therefore, may not have warranted the use of either autograft or Augment Bone Graft. it will be necessary to perform a new clinical study that evaluates the use of Augment Bone Graft as a substitute for autograft in hindfoot and ankle fusion procedures in a well-defined high-risk target population, where the use of autograft would be clinically warranted. the patient population studied in the clinical study, the amount of graft material implanted, and the uncertainty as to whether any graft material would be needed or if the use of no graft material in a fusion procedure of the hindfoot and ankle in the population studied would have achieved similar results. FDA provided a number of additional observations on clinical study design and results. Wright submitted formal appeal to FDA on Sept 5, 2013 On October 31, 2013, Wright was notified by the FDA that the agency has elected to convene a Dispute Resolution Panel to consider the scientific issues in dispute before making a decision on the Company s request that FDA withdraw its August 6, 2013 not approvable letter for Augment Bone Graft. At this time, no date for when Dispute Resolution Panel will be convened 16
2013 Guidance for Continuing Operations Revenue (1) $237M - $240M Adj. EPS (1,2) $(0.55) - $(0.59) 1 Guidance range communicated on 11/4/2013. The fact that we include these projections in this presentation should not be taken to mean that these amounts continue to be our projections as of any subsequent date. 2 Includes stock-based compensation and impact of acquisition of BioMimetic Therapeutics, Inc. 17
W H Y I N V E S T I N W R I G H T M E D I C A L Repositioning for Improved Growth and Performance The Strategy The Platform The Future Focused on areas where we can win Building high-growth, pure play Extremities- Biologics business Clear goal improved performance Accelerated growth, improved profitability, strong cash flow 18
For additional information, please contact: Julie Tracy Chief Communications Officer julie.tracy@wmt.com (901) 290-5817 www.wmt.com NASDAQ: WMGI 19
Investor Presentation November 26, 2013